¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"tumour stem cell assay"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
  • interstitial plasma cell pneumonia
    »çÀÌÁúÇüÁú¼¼Æ÷Æó·Å, ÆóÆ÷ÀÚÃæÁõ
  • Jurkat cell
    Àúı¼¼Æ÷
  • juvenile cell
    À¯¾à¼¼Æ÷
  • juxtaglomerular cell tumor
    Å丮°ç¼¼Æ÷Á¾¾ç, »ç±¸Ã¼¿·¼¼Æ÷Á¾¾ç
  • Kupffer¡¯s cell
    ÄíÆÛ¼¼Æ÷, º°Å«Æ÷½Ä¼¼Æ÷
  • killer cell
    »ìÇØ¼¼Æ÷
  • Langerhans cell
    ¶û°Ô¸£Çѽº¼¼Æ÷
  • Langerhans cell histiocytosis
    ¶û°Ô¸£Çѽº¼¼Æ÷Á¶Á÷±¸Áõ
  • large cell acanthoma
    Å«¼¼Æ÷°¡½Ã¼¼Æ÷Á¾, ´ë¼¼Æ÷±Ø¼¼Æ÷Á¾
  • large cell carcinoma
    ´ë¼¼Æ÷¾ÏÁ¾, Å«¼¼Æ÷¾ÏÁ¾
  • lepra cell
    ³ªº´¼¼Æ÷
  • leukemic cell
    ¹éÇ÷º´¼¼Æ÷
  • Leydig cell tumor
    ¶óÀ̵ðÈ÷¼¼Æ÷Á¾¾ç
  • light cell
    ¹àÀº¼¼Æ÷
  • lipoid cell
    ÁöÁú¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
  • myoepithelial cell
    ±ÙÀ°»óÇǼ¼Æ÷
  • myoid cell
    À¯»ç±ÙÀ°¼¼Æ÷
  • natural killer cell
    ÀÚ¿¬¼¼Æ÷µ¶¼º¼¼Æ÷, ÀÚ¿¬¼¼Æ÷µ¶¼º¼¼Æ÷
  • nerve cell
    ½Å°æ¼¼Æ÷
  • neural crest cell
    ½Å°æ´É¼±¼¼Æ÷
  • neuroendocrine cell
    ½Å°æ³»ºÐºñ¼¼Æ÷
  • neuroepithelial cell
    ½Å°æ»óÇǼ¼Æ÷
  • neuroglial cell
    ½Å°æ¾Æ±³¼¼Æ÷
  • neurosecretory cell
    ½Å°æºÐºñ¼¼Æ÷
  • nevus cell
    ¸ð¹Ý¼¼Æ÷
  • nodal cell
    °áÀý¼¼Æ÷
  • nucleated cell
    À¯ÇÙ¼¼Æ÷
  • null cell
    ¹«Ç¥Áö¼¼Æ÷
  • nurse cell
    (¢¡supporting cell) ¹öÆÀ¼¼Æ÷
  • oat cell carcinoma
    ±Í¸®¼¼Æ÷¾ÏÁ¾
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
  • hairy-cell leukemia
    ¸ð¹ß»ó¼¼Æ÷¹éÇ÷º´
  • heart failure cell
    ½ÉºÎÀü¼¼Æ÷(¡­á¬øà)
  • helmet cell
    Åõ±¸¼¼Æ÷
  • helper T cell
    Á¶·ÂT¼¼Æ÷, º¸Á¶T¼¼Æ÷
  • helper T cell
    º¸Á¶ T¼¼Æ÷
  • helper T cell
    º¸Á¶ T ¼¼Æ÷
  • helper cell
    º¸Á¶¼¼Æ÷
  • helper cell
    Á¶·Â¼¼Æ÷, º¸Á¶¼¼Æ÷
  • helper cell activity
    Á¶·Â¼¼Æ÷´É, º¸Á¶¼¼Æ÷´É
  • hematopoietic cell transplantation
    Á¶Ç÷¼¼Æ÷À̽Ä(¡­á¬øàì¹ãÕ)
  • hemolytic plaque-forming cell
    ¿ëÇ÷¹Ý Çü¼º¼¼Æ÷, ¿ëÇ÷ÇöóÅ© Çü¼º¼¼Æ÷
  • hensens cell
    ¹Ù±ù°æ°è¼¼Æ÷
  • hepatic cell
    °£¼¼Æ÷(ÊÜá¬øà).
  • hepatic cell cord
    °£¼¼Æ÷ÁÙ, °£¼¼Æ÷»è(¡­ßã).
  • heteroploid cell line
    À̼öü¼¼Æ÷°è
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
  • cell cycle
    ¼¼Æ÷ÁÖ±â
  • cell cycle
    ¼¼Æ÷ÁÖ±â
  • cell cycle
    ¼¼Æ÷ÁÖ±â
  • cell cycle
    ¼¼Æ÷ÁÖ±â(¡­ñ²Ñ¢).
  • cell cycle
    ¼¼Æ÷ÁÖ±â
  • cell cycle time
    ¼¼Æ÷ÁÖ±â½Ã°£
  • cell death
    ¼¼Æ÷»ç(á¬øàÞÝ)
  • cell death
    ¼¼Æ÷»ç(á¬øàÞÝ).
  • cell death
    ¼¼Æ÷»ç (¡­ÞÝ)
  • cell deficiency (aganglionic megacolon)
    ¼¼Æ÷ÀÌÁÖ°áÇÌ (¹«½Å°æÀýÁÖ¸§Ã¢ÀÚ
  • cell differentiation
    ¼¼Æ÷ºÐÈ­(¡­ÝÂûù)
  • cell differentiation
    ¼¼Æ÷ºÐÈ­(¡­ÝÂûù).
  • cell distribution
    ¼¼Æ÷ºÐÆ÷
  • cell division
    ¼¼Æ÷ºÐ¿­(¡­ÝÂæñ)
  • cell division
    ¼¼Æ÷ºÐ¿­
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 18
NIA National Institute on Aging; nephelometric inhibition assay; niacin; no information available; Nutri...
OLA left occipitoanterior [fetal position] [Lat. occipito-laeva anterior]; oligonucleotide ligation assa...
PRA panel-reactive antibody; phosphoribosylamine; physician recognition award; plasma renin activity; pr...
PrA-HPA protein A hemolytic plaque assay
REA radiation emergency area; radioenzymatic assay; renal anastomosis; right ear advantage
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 18
EMSA Electrophoretic gel mobility shift assay
EIA Enzyme Immune Assay
EIA Enzyme Immunosorbent Assay
ELLA Enzyme Linked Lectin Assay
ELIFA Enzyme Linked immunofiltration Assay
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • nociceptive dorsal horn cell
    Ä§ÇØ ¼ö¿ë¼º Èİ¢ ¼¼Æ÷, À¯ÇØ ¼ö¿ë¼º Èİ¢ ¼¼Æ÷
  • nociceptive projection cell
    Ä§ÇØ ¼ö¿ë¼º Åõ»ç ¼¼Æ÷, À¯ÇØ ¼ö¿ë¼º Åõ»ç ¼¼Æ÷
  • nociceptive-specific cell
    Ä§ÇØ ¼ö¿ë-ƯÀ̼º ¼¼Æ÷, À¯ÇØ ¼ö¿ë-ƯÀ̼º ¼¼Æ÷
  • non-caseating epithelioid cell granulomata
    ºñ°Ç¶ô¼º À¯»óÇÇ ¼¼Æ÷ À°¾ÆÁ¾
  • non-keratinized squamous cell carcinoma
    ºñ°¢È­¼º ÆíÆò »óÇÇ ¼¼Æ÷ ¾Ï
  • non-nociceptive cell
    ºñÄ§ÇØ ¼ö¿ë¼º ¼¼Æ÷, ºñÀ¯ÇØ ¼ö¿ë¼º ¼¼Æ÷
  • null cell
    ´­ ¼¼Æ÷
    B, T ¼¼Æ÷ Ç¥¸é Ç¥Áö¸¦ °¡ÁöÁö ¾ÊÀº ¸²ÇÁ±¸.
  • off-cell pause
    ²¨Áü ¼¼Æ÷ ÁßÁö
  • on-cell
    ÄÑÁü ¼¼Æ÷
  • osteoprogenitor cell
    °ñ Á¶»ó ¼¼Æ÷, »À Á¶»ó ¼¼Æ÷
    1. °ñÀÇ À¯¸® Ç¥¸é ȤÀº ±× ±Ùó¿¡¼­ º¼ ¼ö ÀÖ´Â ºñ±³Àû ¹ÌºÐÈ­µÈ ¼¼Æ÷·Î¼­, ¾î¶² ȯ°æ¿¡¼­´Â ¼¼Æ÷ ºÐ¿­ÇÏ¿© °ñ¾Æ¼¼Æ÷·Î ÀüȯµÇµç°¡ ȤÀº À¶ÇÕÇÏ¿© ÆÄ°ñ ¼¼Æ÷·Î µÇ±âµµ ÇÑ´Ù. 2. ÀÏ¹Ý °ÉÇÕ Á¶Á÷ÀÇ ¼¼Æ÷µé°ú ¸¶Âù°¡Áö·Î °£Áú Á¶Á÷¿¡¼­ À¯·¡ÇÑ ¼¼Æ÷·Î¼­ À¯»ç ºÐ¿­ ´É·Â°ú »À ¼¼Æ÷·Î ºÐÈ­µÉ ¼ö ÀÖ´Â ´É·ÂÀ» °®°í ÀÖ´Ù. Áß°£¿± ¼¼Æ÷¿Í À¯»çÇϸç, ÇÙÀº ¿°±â¼º ¿°·á¿¡ ¹Ì¾àÇÏ°Ô ¿°»öµÇ°í ¼¼Æ÷ÁúÀº ¾çÀÌ Àû¾î »ê¼º ¿°·á¿¡ ¹Ì¾àÇÏ°Ô ¿°»öµÈ´Ù.
  • oxyntic cell
    »ê ºÐºñ¼º ¼¼Æ÷
    »ê ºÐºñ¼ºÀÇ À§º® ¼¼Æ÷¿Í °°ÀÌ »êÀ» ºÐºñÇÏ´Â ¼¼Æ÷.
  • oxyphil cell
    È£»ê¼º ¼¼Æ÷
  • oxyphilic cell
    È£»ê ¼¼Æ÷, È£»ê¼º ¼¼Æ÷
  • packed cell volume
    ÃæÀü ¼¼Æ÷ ¿ëÀû
  • packed red blood cell
    ³óÃà ÀûÇ÷±¸, ÃæÀü ÀûÇ÷±¸
    1. Ç÷¾×À» ¿ø½É ºÐ¸®ÇßÀ» ¶§ ¹Ù´Ú¿¡ ¹ÐÁýÇØ ÀÖ´Â °Í, ÃæÀü ÀûÇ÷±¸ ºÎÇǸ¦ Ç츶ÅäÅ©¸®Æ®¶óÇÑ´Ù. 2. hematocrit °ü¿¡ äÃëÇÑ ÀüÇ÷À» ÃÖ´ë·Î ¿ø½É ºÐ¸®ÇÏ¿© ¾ò¾îÁö´Â ÀûÇ÷±¸ÀÇ Ä§ÀüÃþ.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 18
tumour promoter <molecular biology, oncology> Agent that in classical studies of carcinogenesis in rodent skin was able to increase the sensitivity of tumour formation by a previously applied primary carcinogen, but was unable to induce tumours when used alone.
Important example was croton oil, active ingredients of which are now believed to be phorbol esters. These are believed to act as analogues of diacylglycerols and may activate protein kinase C. Strictly speaking, not the same as a co carcinogen, which is defined as being active when administered at the same time. Tumour promoters generally are carcinogens when tested more stringently.
(18 Nov 1997)
tumour registry Recorded information about the status of patients with tumours. Although a registry was originally the place (like registry house in edinburgh) where information was collected (in registers), the word registry has also come to mean the collection itself. A tumour registry is organised so the data can be analyzed. For example, analysis of data in a tumour registry maintained at a hospital may show a rise in lung cancer among women.
(12 Dec 1998)
tumour specific antigen <immunology, oncology> Antigen on tumour cells detected by cell-mediated immunity. For virus transformed cells TSTA (unlike T antigen) is found to differ for different individual tumours induced by the same virus. May consist of fragments of T antigens exposed at the cell surface.
(18 Nov 1997)
tumour-specific transplantation antigens Surface antigen's of DNA tumour virus-transformed cells, which elicit an immune rejection of the virus-free cells when transplanted into an animal that has been immunised against the specific cell-transforming virus.
(05 Mar 2000)
tumour stage <oncology> The extent of the spread of a malignant neoplasm from its site of origin.
See: TNM staging.
(05 Mar 2000)
tumour suppressor <molecular biology, oncology> A gene that encodes a product that normally negatively regulates the cell cycle and that must be mutated or otherwise inactivated before a cell can proceed to rapid division.
Examples: p53, RB retinoblastoma), WT 1 (Wilm's tumour), DCC (deleted in colonic carcinoma), NF 1 (neurofibrosarcoma) and APC adenomatous polyposis coli).
(18 Nov 1997)
tumour virus <oncology, virology> Virus capable of inducing tumours.
(18 Nov 1997)
tumour viruses, murine Species of mammalian type c retroviruses (retroviruses type c, mammalian) that cause solid tumours or leukaemias in mice.
(12 Dec 1998)
tumour virus infections Infections produced by oncogenic viruses. The infections caused by DNA viruses are less numerous but more diverse than those caused by the RNA oncogenic viruses.
(12 Dec 1998)
turban tumour Cylindroma of the scalp which, when overgrown, may resemble a turban.
(05 Mar 2000)
Ewing's tumour A malignant primary bone tumour that arises most commonly in the first three decades of life. It is highly malignant (prone to spread) and often requires treatment with some combination of radiation therapy and chemotherapy.
(27 Sep 1997)
faecal tumour An accumulation of inspissated faeces in the colon or rectum giving the appearance of an abdominal tumour.
Synonym: faecal tumour, fecaloma, scatoma, stercoroma.
Origin: copro-+ G. -oma, tumour
(05 Mar 2000)
yaba monkey tumour virus The type species of yatapoxvirus, a tumour-producing DNA virus discovered in monkeys in yaba, nigeria. It has been found to produce histiocytomas in monkeys and humans.
(12 Dec 1998)
Yaba tumour <oncology, virology> A poxvirus-induced neoplasm of African monkeys caused by the Yaba monkey virus, a member of the family Poxviridae.
It is associated with tumour-like growths occur chiefly on the head and limbs. The tumours are benign and the natural disease has been reported only in Africa in monkeys kept outdoors.
(05 Mar 2000)
yolk sac tumour An unusual and aggressive tumour of germ-cell origin that reproduces the extraembryonic structures of the early embryo. It is the most common malignant germ cell tumour found in children. It is characterised by a labyrinthine glandular pattern of flat epithelial cells and rounded papillary processes with a central capillary (schiller-duval body). The tumour is rarely bilateral. Before the use of combination chemotherapy, the tumour was almost invariably fatal.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 18
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 18
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 18
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 18
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 18
ÅëÇÕ°Ë»ö ¿Ï·á